Receptos Inc (RCPT) 169.88 $RCPT French biotech's

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 2:54 PM

Receptos Inc (RCPT) 169.88 $RCPT

French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT

BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)

Active Equities to Watch in the Health Care Sector -- Cytori Therapeutics, Endo Intl., BioMarin Pharma, Novogen, and Receptos
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 93.27 (-0.81), BMRN: 120.28 (-2.67), CYTX: 0.99 (+0.01), RCPT: 169.88 (-1.26), NVGN: 6.54 (-0.01)

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), RCPT: 169.88 (-1.26)

Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 70.26 (-1.52), AVEO: 1.92 (-0.08), RCPT: 169.88 (-1.26), AFFX: 12.44 (-0.16)

Receptos
at Investor's Business Daily - Thu Apr 16, 5:55PM CDT
Receptos (RCPT) reported positive phase-2 study results for ozanimod, its lead drug candidate for ulcerative colitis, meeting all 6 of its primary endpoints for improving the chronic bowel disease after 32 weeks of maintenance. Shares rose 6.1% to...
RCPT: 169.88 (-1.26)

Receptos MS Drug Succeeds Against Ulcerative Colitis
at Investor's Business Daily - Thu Apr 16, 9:50AM CDT
Biotech Receptos (RCPT) reported positive midstage trial results for its lead drug candidate for ulcerative colitis Thursday, sending the stock up as much as 7% in early trading. Receptos said that the phase-two study, called Touchstone, met all six...
JNJ: 101.08 (+0.62), BIIB: 401.71 (-28.57), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)

Receptos ulcerative colitis candidate successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 9:24AM CDT

RCPT: 169.88 (-1.26)

Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
- Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment -
RCPT: 169.88 (-1.26)

Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 81.59 (+0.36), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), LMT: 195.37 (-1.83), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), PBR: 9.99 (+0.59), RDS.B: 63.67 (-0.07), RDS.A: 62.76 (-0.20), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), NAO: 9.77 (-0.26), OA: 72.91 (-1.33), RGR: 56.18 (-0.03), UNP: 107.51 (-0.61), STO: 19.88 (+0.02)

Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
at The Street - Mon Apr 13, 7:19PM CDT
Using traditional analysis, investors might think Netflix is ridiculously expensive compared to where shares traded just a few months or years ago. They'd be wrong, Cramer says.
EMES: 44.65 (-5.95), BX: 41.41 (+0.42), AWAY: 27.18 (-4.99), NOC: 161.78 (-1.05), SFL: 15.63 (-0.01), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), CTXS: 66.99 (-0.35), INFA: 48.16 (+0.16), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), TWTR: 50.82 (-0.59), RGR: 56.18 (-0.03), CSCO: 28.82 (+0.15), PSX: 81.59 (+0.36), ADXS: 23.34 (-0.27), TGTX: 16.23 (-0.18), DISCA: 32.71 (-0.93), FRT: 140.42 (+0.15), NFLX: 558.40 (-0.66), PSG: 20.40 (-0.03), BLKB: 50.30 (-0.17), RVBD: 20.99 (-0.01), RHT: 76.83 (-0.02), STO: 19.88 (+0.02), CBS: 62.72 (+1.09)

Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind
at The Street - Fri Apr 10, 5:01AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BIIB: 401.71 (-28.57), SNSS: 2.69 (+0.04), RCPT: 169.88 (-1.26), MNKD: 4.80 (-0.16), CELG: 118.71 (+2.62)

Stay Away From 3D Printing - Cramer's Lightning Round (4/8/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 09, 5:09AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 8. Bullish Calls: Global Payments (NYSE: GPN ): "It's one of the few upside surprises we have seen so far in 2015. When they are up $6 like...
FSLR: 63.43 (-1.32), VIPS: 28.95 (-0.92), PXD: 174.10 (-1.06), GPN: 101.79 (+0.08), DDD: 27.23 (-2.92), FCX: 20.82 (+0.75), RCPT: 169.88 (-1.26), GOOGL: 573.66 (+16.20), MBT: 11.97 (+0.18), CSIQ: 36.36 (-0.13), GOOG: 565.06 (+18.06), HPQ: 33.26 (-0.12)

'Mad Money' Lightning Round: I'm Not Betting Against Google
at The Street - Thu Apr 09, 5:00AM CDT
Cramer is staying away from 3D Systems, Freeport-McMoRan and Mobile Telesystems but he does like Receptos.
VIPS: 28.95 (-0.92), FSLR: 63.43 (-1.32), PXD: 174.10 (-1.06), GPN: 101.79 (+0.08), DDD: 27.23 (-2.92), RCPT: 169.88 (-1.26), FCS: 18.62 (-0.58), MBT: 11.97 (+0.18), CSIQ: 36.36 (-0.13), GOGL: 5.30 (-0.07)

Jim Cramer's 'Mad Money' Recap: Really, Cheaper Oil Is Good for Stocks
at The Street - Wed Apr 08, 7:21PM CDT
The market got a gift today, says Cramer. So why were investors heading for the hills?
KMI: 44.34 (-0.23), VIPS: 28.95 (-0.92), F: 15.77 (+0.01), PRGO: 192.89 (-8.74), CCL: 46.38 (+0.09), UTX: 116.16 (-1.10), M: 66.99 (-0.43), FCS: 18.62 (-0.58), MBT: 11.97 (+0.18), CSIQ: 36.36 (-0.13), SLB: 91.61 (-1.44), LUV: 43.49 (+0.23), SAVE: 77.42 (+0.43), SONC: 30.83 (-0.21), PLCE: 62.53 (-0.33), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), AAPL: 130.28 (+0.61), HD: 113.70 (-0.26), KR: 71.70 (+0.77), SWKS: 93.39 (-2.43), FB: 81.53 (-0.88), DDD: 27.23 (-2.92), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), BMY: 65.80 (-0.20), FRGI: 54.90 (-4.19), GOGL: 5.30 (-0.07), FSLR: 63.43 (-1.32), PXD: 174.10 (-1.06), GPN: 101.79 (+0.08), GILD: 103.69 (-1.52), TEVA: 64.41 (+1.16), WEN: 10.71 (+0.10)

Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 08, 1:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 23.24 (+0.76), AKAO: 6.36 (-0.04), ZSAN: 8.80 (-0.10), OCUL: 25.36 (-1.12), CACQ: 6.29 (+0.07), VBFC: 19.60 (-0.26), FLML: 15.88 (+0.02), STRS: 14.08 (+0.19), IIIN: 22.03 (+0.13), ANGI: 6.16 (-0.24), RCPT: 169.88 (-1.26), CBMG: 29.51 (-1.85), SCC.TO: 9.50 (+0.15), SRSC: 7.81 (+0.05)

Receptos (RCPT) Marked As A Dead Cat Bounce Stock
at The Street - Wed Apr 08, 8:54AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
RCPT: 169.88 (-1.26)

Weak On High Volume: Receptos (RCPT)
at The Street - Mon Apr 06, 9:08AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a weak on high relative volume candidate
RCPT: 169.88 (-1.26)

Receptos: Unleashing The Beast
DoconStocks - at Seeking Alpha - Thu Apr 02, 12:02PM CDT

RCPT: 169.88 (-1.26), NVS: 104.28 (-1.22)

Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:21AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as the company saw its shares rise over 5% on the day.
ARQL: 2.12 (unch), RCPT: 169.88 (-1.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AVANT BIO Beef Up Team with Heavyweights Lio, Vanek

AVANT BIO's Latest Power Play Alright, here's a big splash in the gene pool of life sciences—AVANT BIO just drafted two industry veterans, Peggy Lio and Philip Vanek, into their Operating Advisor Hall of Fame. And these folks aren't just window dressing. They're packing experience from some of the big hitters like GE Healthcare and Lonza, ready to roll up their sleeves...

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

Epic Oceanside Estate Set for No-Reserve Luxury Auction

Going, Going, Gone? A Golf Exec's Dream Home What's hotter than Florida's summer sun? It's this swanky estate at Ponte Vedra Beach set to hit the auction block without any safety net. Yup, no reserve, folks! Leonard "Len" Brown, Jr., the brains behind many of PGA Tour's global ventures, has decided to put his lavish 3.2-acre plot right by the ocean up for grabs. Once...

Linkurious Named Category Leader in AML Monitoring

Graph Intelligence: The Winning Edge You know, the financial crime scene ain't what it used to be. Gone are the days when a simple audit trail was enough to sniff out dirty money. Companies like Linkurious are pushing the envelope with graph-powered decision intelligence, and in 2026, they got the nod from Chartis Research as a Category Leader for AML Transaction...

Encompass Health Eyes Houston Growth with New Hospital

Fort Bend County: The Next Step in Encompass Health's Journey Kicking off with some Texas flair, Encompass Health is making notable moves in Fort Bend County, venturing to boost its presence in the greater Houston area. It's no surprise given that this neck of the woods is seeing quite the growth spurt lately. Encompass Health, no stranger to living large, is charting new...

PG&E Halts Service; Groups Demand Regulatory Action

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...

Shaking Up Loyalty: TrueLoyal's Bold Move You know, in an era when brands are trying everything to keep customers from jumping ship, getting someone like Erica Thompson on board is like snagging a golden ticket. TrueLoyal just announced they’ve tapped into a veteran, a real heavy-hitter in the loyalty game, to head their loyalty strategy, customer retention, and...

Coastal Financial Faces Lawsuit Amid Massive Stock Hit

Coastal Financial Corporation's (NASDAQ:CCB) recent nosedive is more distressing than a rollercoaster ride. After a 43.52% stock drop, investors are furious, to say the least. What tipped the scales? Coastal's financial revelations painted a bleak picture, but that’s just scratching the surface of a mess that has folks heading for legal battles. Behind the Numbers: The...

Investor Scrutiny Intensifies Over M&A Deals at SGRY, RRC, EQT

When Insiders Seem to Benefit More Ah, mergers and acquisitions—it's the oldest tango in the business world. But today, we've got some footwork that might trip up the small fry. Halper Sadeh LLC, the investor rights bulldogs, are sniffing around Surgery Partners, Range Resources, and EQT. Their quest? To uncover whether the big dogs are playing unfairly with...

OncoHost's Research Links TKI Sensitivity to Biology

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...